TY - JOUR AU - Li, Xinyang AU - Wang, Meiniang AU - Zhang, Xinhua AU - Liu, Chuxin AU - Xiang, Haitao AU - Huang, Mi AU - Ma, Yingying AU - Gao, Xiaoyan AU - Jiang, Lin AU - Liu, Xiaopan AU - Li, Bo AU - Hou, Yong AU - Zhang, Xiuqing AU - Yang, Shuang AU - Yang, Naibo PY - 2020 DA - 2020/02/13 TI - The novel llama-human chimeric antibody has potent effect in lowering LDL-c levels in hPCSK9 transgenic rats JO - Clinical and Translational Medicine SP - 16 VL - 9 IS - 1 AB - The advent of proprotein convertase subtilisin/kexin type 9 (PCSK9)–inhibiting drugs have provided an effective, but extremely expensive treatment for the management of low density lipoprotein (LDL). Our aim was to explore a cost-effective application of camelid anti-PCSK9 single domain antibodies (sdAbs), which are high variable regions of the camelid heavy chain antibodies (VHHs), as a human PCSK9 (hPCSK9) inhibitor. One female llama was immunized with hPCSK9. Screening of high affinity anti-PCSK9 VHHs was carried out based on surface plasmon resonance (SPR) technology. We reported a lysate kinetic analysis method improving the screening efficiency. To increase the serum half-life and targeting properties, the constant region fragment of the human immunoglobulin gamma sub-type 4 (IgG4 Fc) was incorporated to form a novel llama-human chimeric molecule (VHH-hFc). SN - 2001-1326 UR - https://doi.org/10.1186/s40169-020-0265-2 DO - 10.1186/s40169-020-0265-2 ID - Li2020 ER -